Loading...
OTCM
CLAZF
Market cap0USD
May 07, Last price  
0.00USD
Name

Santa Maria Petroleum Inc

Chart & Performance

D1W1MN
OTCM:CLAZF chart
P/E
0.00
P/S
—
EPS
0.11
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
00066,0541,645403,6281,553,000944,402475,1830000000
Net income
4m
P
-148,000-389,000-989,000-3,810,115-3,770,026-8,186,000-22,017,000-24,710,000-20,013,000-51,251-1,404,000-11,554,000-31,863,0006,935,000-21,212,0004,210,000
CFO
-309k
L-95.23%
000-2,407,675-3,024,181-759,318-12,245,075-1,179,811-5,707,315-1,483,228-1,132,000-1,636,000-5,561,000-4,848,000-6,483,000-309,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Operating as a clinical-stage specialty pharmaceutical entity, Claritas Pharmaceuticals, Inc. is dedicated to the creation and market introduction of medical therapies addressing significant patient needs that are currently unfulfilled. Established in 2014, the company was previously known as Kalytera Therapeutics, Inc. before rebranding to Claritas Pharmaceuticals, Inc. in April 2021. Its corporate headquarters are located in San Rafael, California.
URL
https://claritaspharma.com/
IPO date
May 19, 2005
Employees
Domiciled in
US
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT